BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30114221)

  • 1. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised Australian national guidelines for colorectal cancer screening: family history.
    Jenkins MA; Ait Ouakrim D; Boussioutas A; Hopper JL; Ee HC; Emery JD; Macrae FA; Chetcuti A; Wuellner L; St John DJB
    Med J Aust; 2018 Nov; 209(10):455-460. PubMed ID: 30359558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
    Pil L; Fobelets M; Putman K; Trybou J; Annemans L
    Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data.
    Tran B; Keating CL; Ananda SS; Kosmider S; Jones I; Croxford M; Field KM; Carter RC; Gibbs P
    Intern Med J; 2012 Jul; 42(7):794-800. PubMed ID: 21883782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort.
    He E; Lew JB; Egger S; Banks E; Ward RL; Beral V; Canfell K
    Prev Med; 2018 Jan; 106():185-193. PubMed ID: 29109015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years.
    Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE
    Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia.
    Worthington J; Feletto E; Lew JB; Broun K; Durkin S; Wakefield M; Grogan P; Harper T; Canfell K
    Public Health; 2020 Feb; 179():90-99. PubMed ID: 31760206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
    van den Puttelaar R; Nascimento de Lima P; Knudsen AB; Rutter CM; Kuntz KM; de Jonge L; Escudero FA; Lieberman D; Zauber AG; Hahn AI; Inadomi JM; Lansdorp-Vogelaar I
    Gastroenterology; 2024 Jul; 167(2):368-377. PubMed ID: 38552671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.